End-stage	end-stage	O	O	O	O
renal	renal	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
(	(	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
after	after	O	O	O	O
orthotopic	orthotopic	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
(	(	O	O	O	O
OLTX	oltx	O	O	O	O
)	)	O	O	O	O
using	using	O	O	O	O
calcineurin-based	calcineurin-based	O	O	O	O
immunotherapy	immunotherapy	O	O	O	O
:	:	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
development	development	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
calcineurin	calcineurin	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
cyclosporine	cyclosporine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
both	both	O	O	O	O
known	known	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
nephrotoxic	nephrotoxic	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Their	their	O	O	O	O
use	use	O	O	O	O
in	in	O	O	O	O
orthotopic	orthotopic	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
(	(	O	O	O	O
OLTX	oltx	O	O	O	O
)	)	O	O	O	O
has	has	O	O	O	O
dramatically	dramatically	O	O	O	O
improved	improved	O	O	O	O
success	success	O	O	O	O
rates	rates	O	O	O	O
.	.	O	O	O	O

Recently	recently	O	O	O	O
,	,	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
have	have	O	O	O	O
had	had	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
presenting	presenting	O	O	O	O
after	after	O	O	O	O
OLTX	oltx	O	O	O	O
with	with	O	O	O	O
end-stage	end-stage	O	O	O	O
renal	renal	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
(	(	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
retrospective	retrospective	O	O	O	O
study	study	O	O	O	O
examines	examines	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
and	and	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
OLTX	oltx	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
an	an	O	O	O	O
OLTX	oltx	O	O	O	O
only	only	O	O	O	O
from	from	O	O	O	O
June	june	O	O	O	O
1985	1985	O	O	O	O
through	through	O	O	O	O
December	december	O	O	O	O
of	of	O	O	O	O
1994	1994	O	O	O	O
who	who	O	O	O	O
survived	survived	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
postoperatively	postoperatively	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
(	(	O	O	O	O
n=834	n=834	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
prospectively	prospectively	O	O	O	O
collected	collected	O	O	O	O
database	database	O	O	O	O
was	was	O	O	O	O
the	the	O	O	O	O
source	source	O	O	O	O
of	of	O	O	O	O
information	information	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
were	were	O	O	O	O
divided	divided	O	O	O	O
into	into	O	O	O	O
three	three	O	O	O	O
groups	groups	O	O	O	O
:	:	O	O	O	O
Controls	controls	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
or	or	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
,	,	O	O	O	O
n=748	n=748	O	O	O	O
;	;	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
,	,	O	O	O	O
sustained	sustained	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
>	>	O	O	O	O
2.5	2.5	O	O	O	O
mg/dl	mg/dl	O	O	O	O
,	,	O	O	O	O
n=41	n=41	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
,	,	O	O	O	O
n=45	n=45	O	O	O	O
.	.	O	O	O	O

Groups	groups	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
for	for	O	O	O	O
preoperative	preoperative	O	O	O	O
laboratory	laboratory	O	O	O	O
variables	variables	O	O	O	O
,	,	O	O	O	O
diagnosis	diagnosis	O	O	O	O
,	,	O	O	O	O
postoperative	postoperative	O	O	O	O
variables	variables	O	O	O	O
,	,	O	O	O	O
survival	survival	O	O	O	O
,	,	O	O	O	O
type	type	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
survival	survival	O	O	O	O
from	from	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
At	at	O	O	O	O
13	13	O	O	O	O
years	years	O	O	O	O
after	after	O	O	O	O
OLTX	oltx	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
was	was	O	O	O	O
18.1	18.1	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
8.6	8.6	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
9.5	9.5	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Compared	compared	O	O	O	O
with	with	O	O	O	O
control	control	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
and	and	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
had	had	O	O	O	O
higher	higher	O	O	O	O
preoperative	preoperative	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
greater	greater	O	O	O	O
percentage	percentage	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
hepatorenal	hepatorenal	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
,	,	O	O	O	O
higher	higher	O	O	O	O
percentage	percentage	O	O	O	O
requirement	requirement	O	O	O	O
for	for	O	O	O	O
dialysis	dialysis	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
3	3	O	O	O	O
months	months	O	O	O	O
postoperatively	postoperatively	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
1-year	1-year	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Multivariate	multivariate	O	O	O	O
stepwise	stepwise	O	O	O	O
logistic	logistic	O	O	O	O
regression	regression	O	O	O	O
analysis	analysis	O	O	O	O
using	using	O	O	O	O
preoperative	preoperative	O	O	O	O
and	and	O	O	O	O
postoperative	postoperative	O	O	O	O
variables	variables	O	O	O	O
identified	identified	O	O	O	O
that	that	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
compared	compared	O	O	O	O
with	with	O	O	O	O
average	average	O	O	O	O
at	at	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
,	,	O	O	O	O
3	3	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
4	4	O	O	O	O
weeks	weeks	O	O	O	O
postoperatively	postoperatively	O	O	O	O
were	were	O	O	O	O
independent	independent	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
or	or	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
with	with	O	O	O	O
odds	odds	O	O	O	O
ratios	ratios	O	O	O	O
of	of	O	O	O	O
2.6	2.6	O	O	O	O
,	,	O	O	O	O
2.2	2.2	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
1.6	1.6	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

Overall	overall	O	O	O	O
survival	survival	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
time	time	O	O	O	O
of	of	O	O	O	O
OLTX	oltx	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
significantly	significantly	O	O	O	O
different	different	O	O	O	O
among	among	O	O	O	O
groups	groups	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
by	by	O	O	O	O
year	year	O	O	O	O
13	13	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
survival	survival	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
was	was	O	O	O	O
only	only	O	O	O	O
28.2	28.2	O	O	O	O
%	%	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
54.6	54.6	O	O	O	O
%	%	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
developing	developing	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
had	had	O	O	O	O
a	a	O	O	O	O
6-year	6-year	O	O	O	O
survival	survival	O	O	O	O
after	after	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
of	of	O	O	O	O
27	27	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
hemodialysis	hemodialysis	O	O	O	O
versus	versus	O	O	O	O
71.4	71.4	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
developing	developing	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
who	who	O	O	O	O
subsequently	subsequently	O	O	O	O
received	received	O	O	O	O
kidney	kidney	O	O	O	O
transplants	transplants	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
10	10	O	O	O	O
years	years	O	O	O	O
post-OLTX	post-oltx	O	O	O	O
have	have	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
and	and	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
at	at	O	O	O	O
a	a	O	O	O	O
high	high	O	O	O	O
rate	rate	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
decreases	decreases	O	O	O	O
survival	survival	O	O	O	O
,	,	O	O	O	O
particularly	particularly	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
dialysis	dialysis	O	O	O	O
only	only	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
who	who	O	O	O	O
develop	develop	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
have	have	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
preoperative	preoperative	O	O	O	O
and	and	O	O	O	O
1-year	1-year	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
are	are	O	O	O	O
more	more	O	O	O	O
likely	likely	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
hepatorenal	hepatorenal	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
serum	serum	O	O	O	O
creatinine	creatinine	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
various	various	O	O	O	O
times	times	O	O	O	O
postoperatively	postoperatively	O	O	O	O
is	is	O	O	O	O
more	more	O	O	O	O
predictive	predictive	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
CRF	crf	O	DISEASE	OTHERS	I
or	or	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
.	.	O	O	O	O

New	new	O	O	O	O
strategies	strategies	O	O	O	O
for	for	O	O	O	O
long-term	long-term	O	O	O	O
immunosuppression	immunosuppression	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
needed	needed	O	O	O	O
to	to	O	O	O	O
decrease	decrease	O	O	O	O
this	this	O	O	O	O
complication	complication	O	O	O	O
.	.	O	O	O	O

